

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Takashi Shoda, President and Representative Director  
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)  
Please address inquiries to Toshiaki Sai, General Manager,  
Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

### **Daiichi Sankyo Subsidiary to Close Osaka Plant**

**Tokyo, September 30, 2008** – DAIICHI SANKYO COMPANY, LIMITED and its subsidiary Daiichi Sankyo Propharma Co., Ltd. (hereafter DSPP) have announced the closure of the Osaka plant of DSPP. The Boards of Directors of DAIICHI SANKYO and DSPP each reached the decision at the meetings held today and September 27 respectively.

The DAIICHI SANKYO Group is expanding its growth platform to meet the Vision for 2015 (sales of 1.5 trillion yen; operating income ratio of 25% or more; overseas sales ratio of 60% or more). The Group is implementing an optimal global supply system in accordance with the Vision for 2015 to realize a stable global supply and to generate higher profit throughout the supply chain from production to distribution. Restructuring of Japanese domestic plants is one element of these efforts.

The DAIICHI SANKYO Group currently possesses four pharmaceutical formulation plants in Japan. The Osaka plant will be closed after comprehensive evaluation of the current product line, overseas market conditions, status of facilities, current and future production capability, and location among others to respond to the demand in 2015.

Production of main products at the Osaka plant will be transferred to other plants from October 2008 to March 2011 and other products will be outsourced. The plant will be closed in March 2011, and the impact on the FY2008 earnings is minor.

## Overview of Daiichi Sankyo Propharma and its Osaka plant

Daiichi Sankyo Propharma	
Headquarters	1-8 Nihonbashikoamicho, Chuo-ku, Tokyo
Plants	Akita-shi, Akita Onahama (Iwaki-shi, Fukushima) Hiratsuka-shi, Kanagawa Odawara-shi, Kanagawa Shizuoka-shi, Shizuoka Takatsuki-shi, Osaka Osaka-shi, Osaka
Capital	¥100 million (100% owned by DAIICHI SANKYO)
Representative	Masahiro Okabe, President and Representative Director
Sales (FY ended March 2008)	¥85 billion
Employees (as of September 2008)	1,428
Main business	Manufacture (including OEM), sales, and trade of pharmaceutical products

Daiichi Sankyo Propharma Osaka Plant	
Location	Nagara Higashi 2-9-63, Kita-ku, Osaka-shi
Area	25,000 m <sup>2</sup>
Start of operations	1924
Plant manager	Masamichi Katayama
Sales (FY ended March 2008)	¥5.6 billion
Employees (as of September 2008)	130
Main production items	Ethical(prescription) drugs: Loxonin <sup>®</sup> tablets, Mevalotin <sup>®</sup> tablets OTC drugs: Shin-Sankyo Ichoyaku